Gameto

Last chance to vote for our #SXSW panel submission, ‘Transforming Women's Health: From Pain to Progress.’ If you haven’t voted already, please do so at the link below so that we can have this important conversation on the #SXSW stage. Thank you for voting! https://lnkd.in/eTjNbQ6B Dina Radenkovic Maneesh Jain Olivia Sterns Walton Chelsea M.R. Hirschhorn Mirvie Ingeborg Investments Frida

Compelling story about our investor Deena Shakir from Lux Capital and how her experience with postpartum preeclampsia reinforced why she invests in women’s, maternal, and infant health companies like Gameto, Maven Clinic, Alife, and Summer Health. This story sounds way too familiar for so many, even for women who are leaders in the women’s health and biotech spaces. Our CEO and Co-founder Dina Radenkovic was motivated to start Gameto when thinking about her own egg freezing and noticed the lack of innovative solutions in women’s health that prioritize the female patient experience. At Gameto, she helped develop our lead product candidate Fertilo, induced pluripotent stem cell (iPSC)-derived ovarian support cells that mature eggs outside of the body, with the goal of making IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections. Dina was a patient herself in our egg freezing trial, and later on, when giving birth to her first child, Dina’s own uterus was saved by the invention of another women’s health startup, Alydia Health, which was acquired by Organon. We all have skin in the game, and need to continue building and investing in better solutions that prioritize women. Thank you to Deena for sharing your story!

We are excited to share a new publication discussing the focus of our program Fertilo, a cell-based approach to IVM that is made of induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) that mature the eggs outside of the body. Gameto CSO Christian Kramme, PhD and our Clinical Advisor, Pietro Bortoletto, recently collaborated on a paper as part of the European Society of Human Reproduction and Embryology (ESHRE) Journal Club. The ESHRE Journal Club discussion focused on a study by Mostinckx et al. (2024), that reported on experiences with IVM in expected hyper-responders, compared with traditional ovarian stimulation for ICSI. The discussion expanded to possible benefits and limits of IVM, obstacles to overcome for its application in clinical practice and future perspectives. The paper discusses the evolution of IVM from its early challenges to its current potential as a safer, cost-effective alternative to conventional ovarian stimulation in IVF. It highlights the biological rationale, barriers to adoption, and the latest advancements that could enhance IVM's efficacy in clinical practice. Key Takeaways: ➡ IVM offers a safer, less hormone-intensive option for patients, particularly hyper-responders, by reducing the risk of ovarian hyperstimulation syndrome (OHSS). ➡ Recent advancements like CAPA-IVM and OSC-IVM (Fertilo product candidate) improve oocyte maturation and embryo development, making IVM more competitive with traditional IVF. ➡ Widespread adoption of IVM is hindered by technical challenges, varying protocols, and the need for standardized guidelines and training for clinicians and embryologists. We are excited to continue working with this amazing group of researchers and more to continue driving innovation in the IVM field as a treatment option for patients seeking fertility & fertility preservation treatments. Sofia Makieva PhD, Juan J. Fraire-Zamora, Omar Ammar, Georgios Liperis, PhD, Flor Sánchez, PhD, Robert Gilchrist, Claudia Massarotti, Boston IVF, UNSW Link to the full publication here: https://lnkd.in/d_p_jcS5

We are excited to share that Gameto has been nominated for the Best Startup Award by The Galien Foundation! This recognition highlights the commitment and dedication of our team as we continue to work towards redefining the women’s health space. As the Galien Foundation says, “Actors win Oscars, Innovators win Prix Galien USA,” and it is truly an honor to be considered for this prestigious award alongside companies leading the charge in biotech innovation. A huge thank you to our team, partners, and supporters for their relentless efforts and belief in our mission. We look forward to the next steps in this journey and continuing to make a difference in the lives of many. Congratulations to all the nominees and we look forward to the Prix Galien USA forum and awards ceremony in November! Link to the full press release here: https://lnkd.in/ev2cTc29

Vote here to see these four amazing panelists on the #SXSW stage! https://lnkd.in/eTjNbQ6B

Exciting news! Gameto’s South by Southwest’s panel submission has made it to the PanelPicker stage, and we need YOUR help to make it to the conference! The panel, titled ‘Transforming Women's Health: From Pain to Progress,’ features a group of game-changers, from doctors and philanthropists to investors and entrepreneurs, who have used their experiences as catalysts for change. The panel will feature Gameto’s Co-founder and CEO Dina Radenkovic, Ingeborg Investments Founder and CEO Olivia Sterns Walton, Frida Founder and CEO Chelsea M.R. Hirschhorn, and Mirvie’s Co-founder and CEO Maneesh Jain. This is your chance to support a discussion that highlights the work being done to transform the women's health space from all angles. By voting for our panel, you help bring attention to the vital issues and solutions that are shaping the future of healthcare for women. It only takes two minutes to vote, all you need to do is: 🔗 Visit the link below and make an account 📩 Click on the link sent to your email with the subject line “SXSW Account Confirmation” ⬆ Click on the up arrow on the upper right side of the page to submit your vote! Every vote counts, so spread the word and let's make this happen! https://lnkd.in/eTjNbQ6B

Today marks World IVF Day, 46 years since the birth of the world’s first IVF baby, Louise Brown, a groundbreaking achievement that changed the landscape of fertility treatment forever. Since then, it is estimated that over 10 million babies have been born through IVF around the world. IVF is still drastically underutilized, even in a time of increasing infertility rates. Economists cited in the Wall Street Journal believe that the global fertility rate will drop below the population replacement rate very soon if it hasn’t already and predict there will be serious economic, social, and geopolitical consequences if no intervention. In the United States, a shocking 20% of couples reportedly experience infertility; however, only ~4% of couples experiencing infertility actually utilize IVF. While we have made significant progress, there is still a long way to go. At Gameto, we believe that innovations like our product candidate Fertilo are needed to increase access to IVF and egg freezing treatments and improve the patient experience.

Interesting article in The Information featuring Gameto that discusses recent advancements in the fertility tech space and its increasing appeal to VC investors for both financial and personal reasons. Our investor Jack Abraham is mentioned in the article, discussing the personal ties behind his recent investments into fertility tech like Gameto and Orchid. The Information’s Julia Black sat down with our CEO and Co-founder Dina Radenkovic to discuss what Gameto is doing to improve the IVF and egg freezing processes, that are currently brutal, expensive, long and medicalized. They discussed how Gameto’s product candidate, Fertilo, made from ovarian support cells (OSCs) can reduce the hormone injection protocol from two weeks to three days, by mimicking ovarian function outside of the body. Dina said: “We want Gameto to be that science-backed company that thinks about safety and efficacy, but also about the female patient experience.” Thank you to Julia and Margaux for a great conversation and feature! Check out the full article here: https://lnkd.in/e9uz4PuK

Gameto’s Latin America Medical Director, Dr. Carlos Lejtik, will be attending the 60th Mexican Congress of Reproductive Medicine next week in Cancún, Mexico. This is a great chance to learn more about our product candidate Fertilo, an innovative, cell-based approach to in vitro maturation (IVM) that is made of induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs), and discuss potential opportunities for partnering with us in Latin America. Reach out to Carlos Andres Lejtik Alva on either LinkedIn or at carlos@gametogen.com if you are interested in setting up a meeting. We look forward to seeing you there!

As #ISSCR2024 comes to an end, we would like to thank the International Society for Stem Cell Research for another great conference. It was wonderful to get the chance to learn from the brightest minds in stem cell research and hear about all of the amazing work our colleagues are doing to drive forward innovation in the space. We were honored to present our poster, ‘Reproducible and Scalable Differentiation of Ovarian Support Cells from a Clinical-Grade hiPSC Line to be Applied as a Novel in vitro Maturation Strategy for Infertility Treatment,’ that details how Gameto differentiates our ovarian support cells (OSCs) from our donor hiPSC line to create our product candidate, Fertilo. The results presented also showed that OSCs improve both maturation rate and euploid blastocyst formation rate compared to standard of care in vitro maturation (IVM). Thank you again to ISSCR for another great conference! For more information, see this recap of the research we presented: https://lnkd.in/eDhTdidd